Navigation Links
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Date:7/16/2014

REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept  (Enbrel®), in chronic plaque psoriasis (the RaPsOdy trial).  This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis.  The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy.  The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel® in terms of efficacy, safety and immunogenicity.  The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.

"The initiation of the Phase 3 RaPsOdy trial is an important step toward our goal of increasing access to biosimilar etanercept for patients worldwide," said Barbara Finck, M.D., Chief Medical Officer of Coherus.  "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide support for our marketing applications in Europe, the United States, and a number of other countries."

"Based on our evaluation of the analytical, nonclinical and clinical pharmacokinetic similarity of this molecule, we believe that this molecule has met our rigorous internal criteria for initiating our second Phase 3 trial in 2014," said Denny Lanfear, Coherus Chief Executive Officer.  "In concert with our partner Baxter, we are pleased to advance this product into late-stage development."

"With two late-stage trials now underway in partnership with Coherus, we are advancing our col
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 4, 2011 Novo Nordisk announced today the ... application (app) to assist in the diagnosis of ... Kessler, MD, Professor of Medicine and Pathology and ... Lombardi Comprehensive Cancer Center. Coags Uncomplicated features a ...
... 4, 2011 /PRNewswire-Asia-FirstCall/ – Lotus Pharmaceuticals, Inc. (OTC Bulletin ... a fast-growing, profitable developer, manufacturer and seller of medicine ... today announced that it will add two additional stories ... which is currently under construction and is scheduled to ...
Cached Medicine Technology:Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 3
(Date:12/24/2014)... December 24, 2014 For nearly 20 ... housewarmings, new babies, graces, and all of life's rites ... and author, Nancy Tupper Ling, in Toasts: The ... Viva Editions. , Organized by category and containing ... won't appear anywhere else, this timely tome contains sayings ...
(Date:12/24/2014)... 2014 As 2014 draws to a ... before investing time and money into a new or ... that specializes in tankless and eco-friendly products or service. ... water heater in 2015 to research “green” and environmentally ... Greenstar Home Services specializes in eco-friendly and environmentally ...
(Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... steady diet of fast food might hurt your child in ... ate fast food in fifth grade lagged behind by eighth ... more than 8,500 U.S. students. "The largest effects were ... food," said study leader Kelly Purtell, assistant professor of human ...
(Date:12/24/2014)... News) -- Long-term fear of terrorists may damage your heart ... study from Israel suggests. , , Conducted by researchers from ... In Israel, the threat of war and terrorism has been ... "We wanted to test whether fear of terrorism can predict ... study author Hermona Soreq, a professor of molecular neuroscience, said ...
(Date:12/22/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief compliance officer search ... Calif. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... Seal-approved, full-service acute-care hospital serving San Diego County’s coastal ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... (HealthDay News) -- New guidelines on treating so-called "latent" tuberculosis ... the course of the therapy from about 9 months to ... and Prevention. The new guidelines for public health officials ... opinion and the results of three clinical trials -- are ...
... Los Angeles, CA (DECEMBER 8, 2011) Young football players may ... study released in Journal of Child Neurology (JCN), ... and Dr. Meredith R. Golomb looked at various case studies ... and found some potential causes for strokes in young football ...
... Exercise is good medicine, and the number of American adults ... from 31 percent in 1989 to 25 percent in 2008, ... to achieve because certain subgroups of people are highly unlikely ... report from the U.S. Centers for Disease Control and Prevention. ...
... week by the National Institutes of Health has ... cancer should be closely monitored, permitting treatment to ... monitoring strategiessuch as active surveillancehave not been uniformly ... to clear follow-up protocols. The panel recommended standardizing ...
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), ... could be increasing their risk of breast cancer. That ... paper published online ahead of print publication in the ... Journal of Clinical Practice . "No clinical trials ...
Cached Medicine News:Health News:CDC Issues New TB Treatment Guidelines 2Health News:More Americans Exercise, but Arthritis Can Get in the Way 2Health News:Panel endorses active monitoring and delay of treatment for low-risk prostate cancer 2Health News:Panel endorses active monitoring and delay of treatment for low-risk prostate cancer 3Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:Women advised to avoid ZEN bust-enhancing supplements because of possible cancer risk 2
Pneumatic micro sagittal saw, 30k cpm, available with various hose connector styles....
... power line from MicroAire. Our new ... electric instruments, offering the ultimate in ... has always wanted with the security ... Power Master reciprocating saw, Available with ...
... The 7600 Oscillating Saw offers ... osteotomies, thanks to its 14.4V ... cutting head may be rotated ... in any plane and will ...
... Brasseler USAs Large Bone Power System ... offers new technological advancements. The truly innovative ... power pack, which is comprised of the ... handpiece contains only mechanical components, which provides ...
Medicine Products: